Tag Archives: Stephen Brozak

WBB Securities Believes Sarepta Therapeutics (NASDAQ: SRPT) Still Has Room to Grow

WBB Securities analyst Stephen Brozak reiterated a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT) today. The company’s shares opened today at $153.69, close to its 52-week high of $176.50. According to TipRanks.com, Brozak is a 4-star analyst with an average

WBB Securities Sticks to Their Buy Rating for Omeros Corp

In a report released today, Stephen Brozak from WBB Securities reiterated a Buy rating on Omeros Corp (NASDAQ: OMER), with a price target of $75. The company’s shares closed on Friday at $14.09. Brozak commented: “We are therefore continuing our

TapImmune Inc Receives a Buy from WBB Securities

In a report released today, Stephen Brozak from WBB Securities initiated coverage with a Buy rating on TapImmune Inc (NASDAQ: TPIV) and a price target of $5.50. The company’s shares closed yesterday at $3.67. Brozak observed: “We have gained interest

WBB Securities Initiates a Sell Rating on Motif Bio plc

In a report released yesterday, Stephen Brozak from WBB Securities initiated coverage with a Sell rating on Motif Bio plc (NASDAQ: MTFB) and a price target of $7. The company’s shares opened today at $10.81. Brozak said: “We believe there

Celldex Receives a Buy from WBB Securities

WBB Securities analyst Stephen Brozak reiterated a Buy rating on Celldex (NASDAQ: CLDX) today and set a price target of $10. The company’s shares opened today at $2.90. According to TipRanks.com, Brozak is a 4-star analyst with an average return

WBB Securities Believes Corium (NASDAQ: CORI) Won’t Stop Here

In a report issued on July 7, Stephen Brozak from WBB Securities assigned a Buy rating to Corium (NASDAQ: CORI), with a price target of $13. The company’s shares opened today at $8.75, close to its 52-week high of $9.51.